In the biopharmaceutical realm, the harsh reality is a staggering 95% failure rate in human clinical trials, despite promising results in animal testing. However, a rising star in the industry, Vivodyne, is poised to confront this formidable challenge head-on, armed with $40 million in Series A financing and a revolutionary approach to preclinical testing. Vivodyne […]